ReviewJournal of comparative effectiveness research2025

Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China.

Hua Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.